Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cellmid Granted Key Japanese Patent For Anti-Midkine Antibodies

Cellmid (ASX:CDY) has extended global protection for its lead anti-midkine antibody clinical candidate CAB102 and similar antibodies with the award of a Japanese patent.

The grant of patent application 2008-544071 covers the use of anti-midkine antibodies to prevent and treat cancer, inflammatory and autoimmune diseases.

It also covers antibodies to the C-domain of midkine (MK), which has repeatedly been shown to convey most of the disease promoting activities attributed to MK.

Equivalent patents have already been granted in Europe and Australia.

"This granted patent is yet another important piece of Cellmid's comprehensive IP protection for our MK antibodies, including CAB102," managing director Maria Halasz said.

"Cellmid's patent coverage for CAB102 and other therapeutic antibodies now extends across cancer, inflammatory and autoimmune diseases, multiple sclerosis and surgical adhesion."

Cellmid holds the most significant intellectual property assets related to MK worldwide.

Its patent portfolio currently includes 87 patents in 20 patent families, which cover use of MK and anti-MK agents for therapeutic purposes in a number of diseases, as well as the use of MK as a diagnostic marker in cancer and other disorders.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.